Ratings by BNP Paribas Exane (Peter Verdult)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/20/2026 | Sanofi | SNY | Downgrade | Neutral (Outperform) |
47.72 (41.78) |
-12.45% | Details | |
| 8/13/2025 | Novo Nordisk | NVO | Upgrade | Neutral (Underperform) |
49.87 (45.88) |
-8% | Details |
